SEC Form 4 · accession 0001209191-17-023211
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cynthia M Butitta
Officer — Chief Operating Officer
Period of report
Mar 27, 2017
Accepted (ET)
Mar 28, 2017 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 27, 2017 | M | 10,000 | $1.35 | A | 127,795 | D | |
| Common StockF2 | Mar 27, 2017 | S | 300 | $75.74 | D | 127,495 | D | |
| Common StockF3 | Mar 27, 2017 | S | 4,375 | $77.23 | D | 123,120 | D | |
| Common StockF4 | Mar 27, 2017 | S | 4,925 | $78.10 | D | 118,195 | D | |
| Common StockF5 | Mar 27, 2017 | S | 400 | $78.75 | D | 117,795 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F6 | $1.35 | Mar 27, 2017 | M | 10,000 | D | — | Mar 25, 2024 | Common Stock | 10,000 | 145,394 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 24, 2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.28 to $75.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.55 to $77.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.66 to $78.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.72 to $78.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F6108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter.